Evaluation of twenty human adenoviral types and one infectivity-enhanced adenovirus for the therapy of soft tissue sarcoma

Human Gene Therapy

Volumn 18, Issue 1, 2007, Pages 51-62

  Hoffmann, Dennis ^a   Heim, Albert ^b   Nettelbeck, Dirk M ^c,d   Steinstraesser, Lars ^e   Wildner, Oliver ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; IFOSFAMIDE; MEASLES VIRUS FUSOGENIC MEMBRANE GLYCOPROTEIN; ONCOLYTIC ADENOVIRUS; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ADENOVIRUS; ADENOVIRUS 11; ADENOVIRUS 22; ADENOVIRUS 3; ADENOVIRUS 35; ADENOVIRUS 5; ADENOVIRUS 7; ADENOVIRUS 9; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; INTERNALIZATION; MEASLES VIRUS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOLYTIC VIROTHERAPY; SOFT TISSUE SARCOMA; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRION; VIRUS INFECTIVITY; VIRUS STRAIN; VIRUS TYPING; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; MEASLES VIRUS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; OLIGOPEPTIDES; SARCOMA; TRANSDUCTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; VIRUS INTERNALIZATION; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA; COXSACKIEVIRUS; HUMAN ADENOVIRUS TYPE 5; MEASLES VIRUS;

EID: 33846211045     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.132     Document Type: Article

References (72)

1. AHMED, A., JEVREMOVIC, D., SUZUKI, K., KOTTKE, T., THOMPSON, J., EMERY, S., HARRINGTON, K., BATEMAN, A., and VILE, R. (2003). Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy. Gene Ther. 10, 1663-1671.
2. ALEMANY, R., LAI, S., LOU, Y.C., JAN, H.Y., FANG, X., and ZHANG, W.W. (1999). Complementary adenoviral vectors for oncolysis. Cancer Gene Ther. 6, 21-25.
3. v integrins. J. Virol. 74, 7691-7693.
4. BATEMAN, A., BULLOUGH, F., MURPHY, S., EMILIUSEN, L., LAVILLETTE, D., COSSET, F.L., CATTANEO, R., RUSSELL, S.J., and VILE, R.G. (2000). Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res. 60, 1492-1497.
5. BERGELSON, J.M., CUNNINGHAM, J.A., DROGUETT, G., KURTJONES, E.A., KRITHIVAS, A., HONG, J.S., HORWITZ, M.S., CROWELL, R.L., and FINBERG, R.W. (1997). Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323.
6. BRENNAN, M., ALEKTIAR, K., and MAKI, R. (2001). Sarcomas of soft tissue and bone: Soft tissue sarcoma. In Cancer: Principles and Practice of Oncology. (Williams & Wilkins, Philadelphia, PA) pp. 1841-1891.
7. CHOU, J. (1991). Quantitation of synergism and antagonism of two or more drugs by computerized analysis. In Synergism and Antagonism in Chemotherapy. Chou, T.C., and Rideout, D.C., eds. (Academic Press, San Diego, CA) pp. 23-244.
8. CHOU, T.C. (1991). The median-effect principle and the combination index for quantitation of synergism and antagonism. In Synergism and Antagonism in Chemotherapy. Chou, T.C., and Rideout, D.C., eds. (Academic Press, San Diego, CA) pp. 61-102.
9. CHOU, T.C., and HAYBALL, M.P. (1996). CalcuSyn: Windows Software for Dose Effect Analysis [program manual]. BioSoft (Great Shelford, UK).
10. CHOU, T.C., and TALALAY, P. (1984). Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55, 27-55.
11. CRIPE, T.P., DUNPHY, E.J., HOLUB, A.D., SAINI, A., VASI, N.H., MAHLLER, Y.Y., COLLINS, M.H., SNYDER, J.D., KRASNYKH, V., CURIEL, D.T., WICKHAM, T.J., DEGREGORI, J., BERGELSON, J.M., and CURRIER, M.A. (2001). Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus- adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res. 61, 2953-2960.
12. DANIEL, P.T., SCHULZE-OSTHOFF, K., BELKA, C., and GUNER, D. (2003). Guardians of cell death: The Bcl-2 family proteins. Essays Biochem. 39, 73-88.
13. DION, L.D., GOLDSMITH, K.T., STRONG, T.V., BILBAO, G., CURIEL, D.T., and CARVER, R.I.J. (1996). E1A RNA transcripts amplify adenovirus-mediated tumor reduction. Gene Ther. 3, 1021-1025.
14. DMITRIEV, I., KRASNYKH, V., MILLER, C.R., WANG, M., KASHENTSEVA, E., MIKHEEVA, G., BELOUSOVA, N., and CURIEL, D.T. (1998). An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72, 9706-9713.
15. DOUGLAS, J.T., KIM, M., SUMEREL, L.A., CAREY, D.E., and CURIEL, D.T. (2001). Efficient oncolysis by a replicating adenovirus (Ad) in vivo is critically dependent on tumor expression of primary Ad receptors. Cancer Res. 61, 813-817.
16. DUCHROW, M., SCHLUTER, C., WOHLENBERG, C., FLAD, H.D., and GERDES, J. (1996). Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67. Cell Prolif. 29, 1-12.
17. FELSENSTEIN, J. (1997). An alternating least squares approach to inferring phylogenies from pairwise distances. Systematic Biol. 46, 101-111.
18. FU, X., TAO, L., JIN, A., VILE, R., BRENNER, M.K., and ZHANG, X. (2003). Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol. Ther. 7, 748-754.
19. FUEYO, J., GOMEZ-MANZANO, C., ALEMANY, R., LEE, P.S., McDONNELL, T.J., MITLIANGA, P., SHI, Y.X., LEVIN, V.A., YUNG, W.K., and KYRITSIS, A.P. (2000). A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19, 2-12.
20. GAGGAR, A., SHAYAKHMETOV, D.M., and LIEBER, A. (2003). CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 9, 1408-1412.
21. GALANIS, E., BATEMAN, A., JOHNSON, K., DIAZ, R.M., JAMES, C.D., VILE, R., and RUSSELL, S.J. (2001). Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum. Gene Ther. 12, 811-821.
22. GALANIS, E., OKUNO, S.H., NASCIMENTO, A.C., LEWIS, B.D., LEE, R.A., OLIVEIRA, A.M., SLOAN, J.A., ATHERTON, P., EDMONSON, J.H., ERLICHMAN, C., RANDLEV, B., WANG, Q., FREEMAN, S., and RUBIN, J. (2005). Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther. 12, 437-445.
23. GIARD, D.J., AARONSON, S.A., TODARO, G.J., ARNSTEIN, P., KERSEY, J.H., DOSIK, H., and PARKS, W.P. (1973). In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors. J. Natl. Cancer Inst. 51, 1417-1423.
24. HAVENGA, M.J., LEMCKERT, A.A., OPHORST, O.J., VAN MEIJER, M., GERMERAAD, W.T., GRIMBERGEN, J., VAN DEN DOEL, M.A., VOGELS, R., VAN DEUTEKOM, J., JANSON, A.A., DE BRUIJN, J.D., UYTDEHAAG, F., QUAX, P.H., LOGTENBERG, T., MEHTALI, M., and BOUT, A. (2002). Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J. Virol. 76, 4612-4620.
25. HE, T.C., ZHOU, S., DA COSTA, L.T., YU, J., KINZLER, K.W., and VOGELSTEIN, B. (1998). A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U.S.A. 95, 2509-2514.
26. HOFFMANN, D., and WILDNER, O. (2006a). Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy. Mol. Cancer Ther. 5, 2013-2022.
27. HOFFMANN, D., and WILDNER, O. (2006b). Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli. BMC Biotechnol. 6, 36.
28. HOFFMANN, D., BANGEN, J.M., BAYER, W., and WILDNER, O. (2006). Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer. Gene Ther. 13, 1534-1544.
29. HORIKAWA, I., CABLE, P.L., AFSHARI, C., and BARRETT, J.C. (1999). Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res. 59, 826-830.
30. INOUE, H., TANABE, T., and UMESONO, K. (2000). Feedback control of cyclooxygenase-2 expression through PPARγ. J. Biol. Chem. 275, 28028-28032.
31. JEMAL, A., THOMAS, A., MURRAY, T., and THUN, M. (2002). Cancer statistics, 2002. CA Cancer J. Clin. 52, 23-47.
32. KHURI, F.R., NEMUNAITIS, J., GANLY, I., ARSENEAU, J., TANNOCK, I.F., ROMEL, L., GORE, M., IRONSIDE, J., MACDOUGALL, R.H., HEISE, C., RANDLEV, B., GILLENWATER, A.M., BRUSO, P., KAYE, S.B., HONG, W.K., and KIRN, D.H. (2000). A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879-885.
33. KIMURA, M. (1980). A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J. Mol. Evol. 16, 111-120.
34. LEE, C.T., PARK, K.H., YANAGISAWA, K., ADACHI, Y., OHM, J.E., NADAF, S., DIKOV, M.M., CURIEL, D.T., and CARBONE, D.P. (2004). Combination therapy with conditionally replicating adenovirus and replication defective adenovirus. Cancer Res. 64, 6660-6665.
35. LEMCKERT, A.A., GRIMBERGEN, J., SMITS, S., HARTKOORN, E., HOLTERMAN, L., BERKHOUT, B., BAROUCH, D.H., VOGELS, R., QUAX, P., GOUDSMIT, J., and HAVENGA, M.J. (2006). Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: Manufacture on PER.C6 cells, tropism and immunogenicity. J. Gen. Virol. 87, 2891-2899.
36. LEON, R.P., HEDLUND, T., MEECH, S.J., LI, S., SCHAACK, J., HUNGER, S.P., DUKE, R.C., and DEGREGORI, J. (1998). Adenoviral-mediated gene transfer in lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 95, 13159-13164.
37. LI, H., HAVIV, Y.S., DERDEYN, C.A., LAM, J., COOLIDGE, C., HUNTER, E., CURIEL, D.T., and BLACKWELL, J.L. (2001). Human immunodeficiency virus type 1-mediated syncytium formation is compatible with adenovirus replication and facilitates efficient dispersion of viral gene products and de novo-synthesized virus particles. Hum. Gene Ther. 12, 2155-2165.
38. LI, Y., PONG, R.C., BERGELSON, J.M., HALL, M.C., SAGALOWSKY, A.I., TSENG, C.P., WANG, Z., and HSIEH, J.T. (1999). Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy. Cancer Res. 59, 325-330.
39. LUKASHOK, S.A., and HORWITZ, M.S. (1998). New perspectives in adenoviruses. Curr. Clin. Top. Infect. Dis. 18, 286-305.
40. MADISCH, I., HARSTE, G., POMMER, H., and HEIM, A. (2005). Phylogenetic analysis of the main neutralization and hemagglutination determinants of all human adenovirus prototypes as a basis for molecular classification and taxonomy. J. Virol. 79, 15265-15276.
41. MAIZEL, J.V., JR., WHITE, D.O., and SCHARFF, M.D. (1968). The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 36, 115-125.
42. MARTTILA, M., PERSSON, D., GUSTAFSSON, D., LISZEWSKI, M.K., ATKINSON, J.P., WADELL, G., and ARNBERG, N. (2005). CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7. J. Virol. 79, 14429-14436.
43. MEIER, O., and GREBER, U.F. (2004). Adenovirus endocytosis. J. Gene Med. 6(Suppl. 1), S152-S163.
44. MITTEREDER, N., MARCH, K.L., and TRAPNELL, B.C. (1996). Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70, 7498-7509.
45. NAKAMURA, T., PENG, K.W., VONGPUNSAWAD, S., HARVEY, M., MIZUGUCHI, H., HAYAKAWA, T., CATTANEO, R., and RUSSELL, S.J. (2004). Antibody-targeted cell fusion. Nat. Biotechnol. 22, 331-336.
46. NILSSON, M., LJUNGBERG, J., RICHTER, J., KIEFER, T., MAGNUSSON, M., LIEBER, A., WIDEGREN, B., KARLSSON, S., and FAN, X. (2004). Development of an adenoviral vector system with adenovirus serotype 35 tropism; Efficient transient gene transfer into primary malignant hematopoietic cells. J. Gene Med. 6, 631-641.
47. RAM, Z., CULVER, K.W., OSHIRO, E.M., VIOLA, J.J., DEVROOM, H.L., OTTO, E., LONG, Z., CHIANG, Y., McGARRITY, G.J., MUUL, L.M., KATZ, D., BLAESE, R.M., and OLDFIELD, E.H. (1997). Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med. 3, 1354-1361.
48. RAUEN, K.A., SUDILOVSKY, D., LE, J.L., CHEW, K.L., HANN, B., WEINBERG, V., SCHMITT, L.D., and McCORMICK, F. (2002). Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: Potential relevance to gene therapy. Cancer Res. 62, 3812-3818.
49. RICHARDSON, C.D., SCHEID, A., and CHOPPIN, P.W. (1980). Specific inhibition of paramyxovirus and myxovirus replication by oligopeptides with amino acid sequences similar to those at the N-termini of the F1 or HA2 viral polypeptides. Virology 105, 205-222.
50. ROELVINK, P.W., KOVESDI, I., and WICKHAM, T.J. (1996). Comparative analysis of adenovirus fiber-cell interaction: Adenovirus type 2 (Ad2) and Ad9 utilize the same cellular fiber receptor but use different binding strategies for attachment. J. Virol. 70, 7614-7621.
51. ROELVINK, P.W., LIZONOVA, A., LEE, J.G., LI, Y., BERGELSON, J.M., FINBERG, R.W., BROUGH, D.E., KOVESDI, I., and WICKHAM, T.J. (1998). The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J. Virol. 72, 7909-7915.
52. SEGERMAN, A., ARNBERG, N., ERIKSON, A., LINDMAN, K., and WADELL, G. (2003a). There are two different species B adenovirus receptors: sBAR, common to species B1 and B2 adenoviruses, and sB2AR, exclusively used by species B2 adenoviruses. J. Virol. 77, 1157-1162.
53. SEGERMAN, A., ATKINSON, J.P., MARTTILA, M., DENNERQUIST, V., WADELL, G., and ARNBERG, N. (2003b). Adenovirus type 11 uses CD46 as a cellular receptor. J. Virol. 77, 9183-9191.
54. SHAYAKHMETOV, D.M., and LIEBER, A. (2000a). Dependence of adenovirus infectivity on length of the fiber shaft domain. J. Virol. 74, 10274-10286.
55. + cells by a retargeted adenovirus vector. J. Virol. 74, 2567-2583.
56. SHORT, J.J., PEREBOEV, A.V., KAWAKAMI, Y., VASU, C., HOLTERMAN, M.J., and CURIEL, D.T. (2004). Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology 322, 349-359.
57. SIRENA, D., LILIENFELD, B., EISENHUT, M., KALIN, S., BOUCKE, K., BEERLI, R.R., VOGT, L., RUEDL, C., BACHMANN, M.F., GREBER, U.F., and HEMMI, S. (2004). The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J. Virol. 78, 4454-4462.
58. SMITH, C.D., CRAFT, D.W., SHIROMOTO, R.S., and YAN, P.O. (1986). Alternative cell line for virus isolation. J. Clin. Microbiol. 24, 265-268.
59. TAKEUCHI, S., ITOH, N., UCHIO, E., TANAKA, K., KITAMURA, N., KANAI, H., ISOBE, K., AOKI, K., and OHNO, S. (1999). Adenovirus strains of subgenus D associated with nosocomial infection as new etiological agents of epidemic keratoconjunctivitis in Japan. J. Clin. Microbiol. 37, 3392-3394.
60. TOMKO, R.P., XU, R., and PHILIPSON, L. (1997). HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. U.S.A. 94, 3352-3356.
61. VOLK, A.L., RIVERA, A.A., KANERVA, A., BAUERSCHMITZ, G., DMITRIEV, I., NETTELBECK, D.M., and CURIEL, D.T. (2003). Enhanced adenovirus infection of melanoma cells by fiber-modification: Incorporation of RGD peptide or Ad5/3 chimerism. Cancer Biol. Ther. 2, 511-515.
62. WADELL, G., HAMMARSKJOLD, M.L., WINBERG, G., VARSANYI, T.M., and SUNDELL, G. (1980). Genetic variability of adenoviruses. Ann. N. Y. Acad. Sci. 354, 16-42.
63. 5 promote adenovirus internalization but not virus attachment. Cell 73, 309-319.
64. 5 selectively promotes adenovirus mediated cell membrane permeabilization. J. Cell Biol. 127, 257-264.
65. WILDNER, O., MORRIS, J.C., VAHANIAN, N.N., FORD, H.J., RAMSEY, W.J., and BLAESE, R.M. (1999). Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther. 6, 57-62.
66. WILSON, J.M. (1996). Adenoviruses as gene-delivery vehicles. N. Engl. J. Med. 334, 1185-1187.
67. WITLOX, A.M., VAN BEUSECHEM, V.W., MOLENAAR, B., BRAS, H., SCHAAP, G.R., ALEMANY, R., CURIEL, D.T., PINEDO, H.M., WUISMAN, P.I., and GERRITSEN, W.R. (2004). Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo. Clin. Cancer Res. 10, 61-67.
68. WITLOX, M.A., VAN BEUSECHEM, V.W., GRILL, J., HAISMA, H.J., SCHAAP, G., BRAS, J., VAN DIEST, P., DE CAST, A., CURIEL, D.T., PINEDO, H.M., GERRITSEN, W.R., and WUISMAN, P.I. (2002). Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma. J. Gene Med. 4, 510-516.
69. WOLKERSDORFER, G.W., MORRIS, J.C., EHNINGER, G., and RAMSEY, W.J. (2004). Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma. J. Gene Med. 6, 652-662.
70. WU, E., PACHE, L., VON SEGGERN, D.J., MULLEN, T.M., MIKYAS, Y., STEWART, P.L., and NEMEROW, G.R. (2003). Flexibility of the adenovirus fiber is required for efficient receptor interaction. J. Virol. 77, 7225-7235.
71. WU, E., TRAUGER, S.A., PACHE, L., MULLEN, T.M., VON SEGGERN, D.J., SIUZDAK, G., and NEMEROW, G.R. (2004). Membrane cofactor protein is a receptor for adenoviruses associated with epidemic keratoconjunctivitis. J. Virol. 78, 3897-3905.
72. ZHANG, Y., and BERGELSON, J.M. (2005). Adenovirus receptors. J. Virol. 79, 12125-12131.